A diagnostic algorithm for metabolic myopathies, 2010. ,
, Curr. Neurol. Neurosci. Rep, vol.10, pp.118-126
Metabolic myopathies: clinical features and diagnostic approach, Rheum. Dis. Clin. North Am, vol.37, pp.201-217, 2011. ,
Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects, Mol. Aspects. Med, vol.25, pp.495-520, 2004. ,
Fiber types in mammalian skeletal muscles, Physiol. Rev, vol.91, pp.1447-1531, 2011. ,
Exercise metabolism and the molecular regulation of skeletal muscle adaptation, Cell. Metab, vol.17, pp.162-184, 2013. ,
Molecular networks in skeletal muscle plasticity, J. Exp. Biol, vol.219, pp.205-213, 2016. ,
Complex Coordination of Cell Plasticity by a PGC-1alpha-controlled Transcriptional Network in Skeletal Muscle, Front. Physiol, vol.6, p.325, 2015. ,
Expanding roles for AMPK in skeletal muscle plasticity, Trends Endocrinol. Metab, vol.26, pp.275-286, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01171734
The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis, Am. J. Physiol. Cell. Physiol, vol.303, pp.475-485, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-02652061
Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism, Endocr. Rev, vol.27, pp.728-735, 2006. ,
Transcriptional integration of mitochondrial biogenesis, Trends Endocrinol. Metab, vol.23, pp.459-466, 2012. ,
Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1, Cell, vol.98, pp.115-124, 1999. ,
,
Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres, Nature, vol.418, pp.797-801, 2002. ,
Regulation of PGC-1alpha, a nodal regulator of mitochondrial biogenesis, Am. J. Clin. Nutr, vol.93, pp.884-890, 2011. ,
An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle, Proc. Natl. Acad. Sci. U S A, vol.100, pp.7111-7116, 2003. ,
,
PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes, Cell. Metab, vol.4, pp.407-414, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00188136
,
, AMP-activated protein kinase phosphorylates transcription factors of the CREB family, J. Appl. Physiol, vol.104, pp.429-438, 1985.
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha, Proc. Natl. Acad. Sci. U S A, vol.104, pp.12017-12022, 2007. ,
AMP-activated protein kinase and its downstream transcriptional pathways, Cell. Mol. Life Sci, vol.67, pp.3407-3423, 2010. ,
AMPK: guardian of metabolism and mitochondrial homeostasis, Nat. Rev. Mol. Cell. Biol, vol.19, pp.121-135, 2018. ,
Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress, Science, vol.351, pp.275-281, 2016. ,
,
Regulation of autophagy in human skeletal muscle: effects of exercise, exercise training and insulin stimulation, J. Physiol, vol.594, pp.745-761, 2016. ,
Autophagy plays a role in skeletal muscle mitochondrial biogenesis in an endurance exercise-trained condition, J. Physiol. Sci, vol.66, pp.417-430, 2016. ,
Regulation of the autophagy system during chronic contractile activityinduced muscle adaptations, Physiol. Rep, vol.5, p.28, 2017. ,
,
, Autophagy is required for exercise training-induced skeletal muscle adaptation and improvement of physical performance, FASEB J, vol.27, pp.4184-4193
, Patent WO 2012119978A1 Quinolinone derivatives as activators of AMPK, 2012.
Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade, Biochem. J, vol.403, pp.139-148, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00478681
Application of tandem mass spectrometry to biochemical genetics and newborn screening, Clin. Chim. Acta, vol.322, pp.1-10, 2002. ,
,
Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders, J. Inherit. Metab. Dis, vol.23, pp.27-44, 2000. ,
,
EMG-normalised kinase activation during exercise is higher in human gastrocnemius compared to soleus muscle, PLoS One, vol.7, p.31054, 2012. ,
,
AMP-activated protein kinase activity and subunit expression in exercise-trained human skeletal muscle, J. Appl. Physiol, vol.5, pp.631-641, 1985. ,
The hitchhiker's guide to PGC-1alpha isoform structure and biological functions, Diabetologia, vol.58, pp.1969-1977, 2015. ,
Adaptations of skeletal muscle to exercise, 2002. ,
, , vol.16, pp.1879-1886
The truncated splice variants, NT-PGC-1alpha and PGC-1alpha4, increase with both endurance and resistance exercise in human skeletal muscle, Physiol. Rep, vol.1, p.140, 2013. ,
,
Alternative mRNA splicing produces a novel biologically active short isoform of PGC-1alpha, J. Biol. Chem, vol.284, pp.32813-32826, 2009. ,
Genetic and cellular modifiers of oxidative stress: what can we learn from fatty acid oxidation defects?, Mol. Genet. Metab, vol.110, pp.31-39, 2013. ,
Reactive oxygen species are signalling molecules for skeletal muscle adaptation, Exp. Physiol, vol.95, pp.1-9, 2010. ,
Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions, Mitochondrion, vol.7, pp.39-44, 2007. ,
Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress, Science, vol.351, pp.275-281, 2016. ,
Regulation of mitochondrial fatty acid beta-oxidation in human: what can we learn from inborn fatty acid beta-oxidation deficiencies?, Biochimie, vol.96, pp.113-120, 2014. ,
Bezafibrate for treatment of an inborn mitochondrial ß-oxidation defect, N. Engl. J. Med, vol.360, pp.838-840, 2009. ,
,
Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency, Clin. Pharmacol. Ther, vol.88, pp.101-108, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-02896226
Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts, Hum. Mol. Genet, vol.20, pp.2048-2057, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02894854
Peroxisome Proliferator Activated Receptor delta (PPAR?) Agonist But Not PPAR? Corrects Carnitine Palmitoyl Transferase 2 Deficiency in Human Muscle Cells, J. Clin. Endocrinol. Metab, vol.90, pp.1791-1797, 2005. ,
Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate, Pediatr. Res, vol.54, pp.446-451, 2003. ,
,
Beneficial effects of resveratrol on respiratory chain defects in patients' fibroblasts involve estrogen receptor and estrogen-related receptor alpha signaling, Hum. Mol. Genet, vol.23, pp.2106-2119, 2014. ,
URL : https://hal.archives-ouvertes.fr/inserm-02894840
Mechanism and medical implications of mammalian autophagy, Nat. Rev, 2018. ,
, Mol. Cell. Biol, vol.19, pp.349-364
AMPactivated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside, Biochem. J, vol.404, pp.499-507, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00478741
Reactive oxygen species in skeletal muscle signaling, J. Signal Transduct, vol.982794, pp.1-17, 2012. ,
Exercise-induced hormesis and skeletal muscle health. Free Radic, Biol. Med, vol.98, pp.113-122, 2016. ,
The role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymes, J. Muscle Res. Cell. Motil, vol.36, pp.377-393, 2015. ,
Muscle redox disturbances and oxidative stress as pathomechanisms and therapeutic targets in early-onset myopathies, Semin. Cell. Dev. Biol, vol.64, pp.213-223, 2017. ,
Characterization of fatty acid oxidation in human muscle mitochondria and myoblasts, Mol. Genet. Metab, vol.78, pp.112-118, 2003. ,
URL : https://hal.archives-ouvertes.fr/inserm-02896304
Protein measurement with the folin phenol reagent, J. Biol. Chem, vol.193, pp.265-275, 1951. ,
Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities, Eur. J. Biochem, vol.186, pp.129-136, 1989. ,
Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay, Eur. J. Biochem, vol.186, pp.123-128, 1989. ,
, Figure 3. GSK773 corrects the impaired differentiation process in CPT2-deficient myotubes
, Representative kinetics of muscle cells during proliferation and differentiation using xCELLigence system
, Histograms of cell index at different times; (n=6-10 experiments)
, Representative kinetics of muscle cells treated with 30µM GSK773 during proliferation and differentiation, the blue arrows represent the treatments
, Maximum cell index of myotubes treated for 10 days
, Representative immunofluorescence images: MHC-I (green), CPT2 (red) and Topro-3-labeled nuclei (blue)
, Fatty acid oxidation flux measured in myotubes treated for 10 days
, Data are means ± SEM. *p<0.05, **p<0.01 compared with vehicle-treated myotubes
, AMPK is constitutively phosphorylated in CPT2 patients, and AMPK and PGC-1? are involved in signaling pathway triggered by GSK773
, Representative western blots of AMPK?1 and P-AMPK (n=4-6 experiments)
, Quantification of P-AMPK protein levels in myotubes (30 µM GSK773, 48h)
,
, Representative western blots of AMPK?1, CPT2 and MHC-I. Myotubes were transfected with siNon-target (NT) or siAMPK?1 at day 2 of differentiation, were allowed to differentiate 2 more days and were then treated with 30 µM GSK773 for 48h
, Quantification of CPT2 protein levels in transfected myotubes
, Quantification of MHC-I protein levels in transfected myotubes
, Representative western blots of CPT2 and MHC-I from myotubes transfected with siNon-target (NT) or siPGC-1?, and treated with 30 µM GSK773 for 48h
, Quantification of CPT2 protein levels in transfected myotubes (n= 5 independent experiments)
, Quantification of MHC-I protein levels in transfected myotubes (n= 3-5 independent experiments)
, Data are means ± SEM. *p<0.05, **p<0.01, ***p<0.001 versus vehicle-treated myotubes, p.33
, Figure 5. ROS and p38-MAPK are involved in signaling pathway triggered by GSK773
, Relative measurement of total cellular reactive oxygen species (ROS) production in myotubes, after 48h of treatment with 30µM GSK773 (n=3 independent experiments)
, Representative fluorescence images of myotubes loaded with the ROS sensor CM-H2DCFDA
, Representative western blots of p38-MAPK and P-p38-MAPK (n=3 different experiments)
, Quantification of P-p38 protein levels in myotubes (30 µM GSK773, 48h)
, Representative western blots of CPT2 and MHC-I from myotubes treated with 30µM GSK773 for 48h in conjunction with 10mM N-acetyl-cysteine (NAC) or 10µM SB203580 (myotubes were pre-treated with the p38 inhibitor 30min prior addition of GSK773)
, Quantification of CPT2 protein levels (n= 4 independent experiments
, Quantification of MHC-I protein levels (n=4 independent experiments)
, Proposed schematic model of the effects of GSK773 on CPT2 and MHC-I
, Data are means ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared with vehicle-treated myotubes
, Figure 6. GSK773 acts on mitochondrial biogenesis and on mitochondrial network
, Quantification of citrate synthase protein levels in myotubes
, Quantification of Tfam and COX2 protein levels; (n=3-6 experiments)
, Immunofluorescence images of 10 days-treated myotubes: CPT2 (red) and Topro-3-labeled nuclei (blue) at x40 magnification and (D) x80 magnification
, Quantification of DRP1 protein levels in myotubes (30 µM GSK773, 48h); (n=4-6 experiments)
, Quantification of MFN2 protein levels in myotubes (30 µM GSK773, 48h); (n=5-6 experiments)
, Representative western blots of LC3-I and LC3-II (n=3 different experiments)
, Quantification of LC3-I + LC3-II protein levels
, Quantification of LC3-II protein levels